Monday

Plenary
Welcome addresses **Keynote welcome speaker (tba)**
Session 1: Radiobiology in therapy and space science *(Chair: Marco Durante, Gillies McKenna)*
• Invited talk: S. Ting (MIT, USA) "Active shielding for interplanetary flights" (tbc) • Selected Abstracts
Coffee
• Invited talk: P. O'Neill (University of Oxford, UK) "Molecular basis for the relative biological effectiveness of densely ionizing radiation" • Selected Abstracts
Session 2: Radioisotopes in diagnostics and therapy *(Chair: Jean-François Chatal, Ulli Köster)*
• Opening talk: Patrick Bourguet (EANM President) - The importance of radioisotopes for nuclear medicine (tbc) • Invited talk: Marion de Jong (Rotterdam) - Preclinical imaging and therapy • Selected Abstracts
Coffee
• Invited talk: Michael Zalutsky (Durham) - Targeted alpha therapy • Selected Abstracts

Tuesday

Plenary
Session 3: Prospects in detectors and medical imaging *(Chair: Alberto Del Guerra, Wolfgang Enghardt)*
• Invited talk: S. Ziegler (Munich) - The technology of solid state detectors in Nuclear Medicine • Selected Abstracts
10:15 Coffee
• Invited talk: O. Ratib (Geneva) - Hybrid systems in Medical Imaging: from PET/CT to PET/MR • Selected Abstracts
Session 4: Novel Technologies in Radiation Therapy *(Chair: Ugo Amaldi, Ken Peach)*
• Invited talk: M. Pullia (CNAO) - Gantries for carbon ion therapy • Invited talk: M. Schippers (PSI) - Novel techniques in proton therapy • Selected Abstracts
Coffee
• Invited talk: C. Bert (GSI) - Treating moving organs with particle beams • Selected Abstracts
Public talk by S.M. Bentzen, USA

Wednesday

Plenary		
ESTRO Lecture ***Chair: J. Bourhis (F)***		
• P. Lambin (NL) "Knowledge Engineering in Radiation Oncology: the start of a paradigm shift?"		
Plenary Lectures		
• J.P. Gerard (FR) "Physics meets clinics" • W. Enghardt (D) "In-room imaging" • D. Packer (US) "Ion treatment of Atrial Fibrillation" • R. Baum (D) "Targeted radionuclide therapy" • E. Malinen (FIN) "Adapting biological feedback in radiotherapy" • M. van Herk (NL) "Improving precision in imaging and treatment"		
Session 1	**Session 2**	**Session 3**
Tumour targeting and normal tissue protection	**Image-guided prescription and planning of RT**	**Long-term perspectives in Hadrontherapy**
• Multimodality imaging for tumour targeting in prostate cancer K. Haustermans, B • TBA • TBA	• Bio-IGRT. D. Zips, D • TBA • TBA	• Particle therapy - leveraging clinical performance ? D.R. Olsen, NOR • Translational approaches in carbon Ion radiotherapy. J. Debus, D • TBA

New algorithms in treatment planning and delivery	Montecarlo in treatment planning	Status and perspectives in radiology
• Failure mode and effect analysis-based quality assurance for dynamic MLC tracking systems: Patient safety in the era of real-time radiotherapy P. Keall • TBA • TBA	• TBA • TBA • TBA	• TBA • TBA • TBA

Thursday

Plenary: G.H. Fletcher Lecture *Chair: K.K. Ang (USA)* Translating biology into high-technology radiotherapy (M. Baumann, D)		
Session 1	Session 2	Session 3
From tumor biology to functional imaging ***Chair: B. Wouters (CAN), M. Ozsahin (CH)***	**Clinical radiation research** ***Chair: R. Miralbell (CH), P. Lambin (NL)***	**Mitigation/repair of radiation damage: stem cells, modifiers, interventions** ***Chair: S. Powell (USA), R. Mirimanoff (CH)***
• Tumor microenvironmental reactions influencing response to radiotherapy. C. Rüegg, CH • Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. J.T. Erler, UK	• Cancer stem cell-related biomarkers with predictive potential for radiotherapy. M. Krause, D • Learning from the past – normal tissue toxicity in retrospective studies. I. Vogelius, DK • Dose-fractionation sensitivity of prostate cancer. R. Miralbell, CH • Open prediction of expected gain from proton therapy in individual patients based on NTCP predictive modeling: final results of ALLEGRO project. J.A. Langendijk, NL	• The development of salivary gland stem cell therapy for radiation-induced hyposalivation. S.A. Pringle, NL • Glioma cell migration in 3D is not impaired by ionizing irradiation. N. Cordes, D • Decreasing the adverse effects of cancer therapy: guidance for clinical development of radiation injury mitigators. M. Hauer-Jensen, USA
Coffee Break		
EORTC session ***Chair: V. Gregoire (B)***	**Oral Poster presentations** ***Chair: J. Bernier (CH)***	**Oral Poster presentations** ***Chair: R. Komaki (USA)***
• Opening of the session. V. Gregoire, B • Current and future clinical research in radiotherapy. V. Gregoire, B • Recent developments in imaging and	• Abstract n. 271: S. Tomatis (I) - Predicting rectal bleeding with neural networks: late effects on patients treated for prostate cancer with 3DCRT • Abstract n. 281: A. Hope (CAN) - Increased acute symptoms of radiation pneumonitis with concurrent	• Abstract n. 34: P.T. Tran (USA) - Hedgehog pathway inhibition and radiotherapy for non-small cell lung cancer • Abstract n. 332: E. Ford (USA) – Localized radiation disrupts the migration of neural progenitor cells

translational research in radiotherapy.
D. Lacombe, B

- Quality Assurance in radiotherapy: the EORTC experience.
  D. Weber, CH
- Does quality of radiotherapy predict outcomes of multicenter clinical trials? The EORTC ROG experience.
  A. Fairchild, B

chemoradiotherapy vs. radiotherapy alone in a murine model of fractionated sub-total thoracic IGRT

- Abstract n.286: A. Konski (USA) – Dosimetric modeling of cardiac toxicity in patients with esophageal cancer receiving radiotherapy
- Abstract n. 135: A. Staab (D) - Hyperthermia radiosensitizes hypoxic HCT-116 human colorectal carcinoma cells in vitro
- Abstract n. 137: S. Graf (D) - Robustness against the interfractional internal target movement in ion beam radiotherapy prostate treatment planning
- Abstract n. 154: A.O. Fontana (CH) - Proton versus Photon Radiotherapy: Differential Demands on the Biological Level
- Abstract n. 189: D. Abler (CH) - Meta-modelling Markov Model Simulations for cost effectiveness analyses
- Abstract n. 98: S. Ahmed (UK) - A Radiation sensitivity and DNA damage responses in glioma stem cells
- Abstract n. 199: L. Brondum (DK) - Predictive and prognostic markers in serum/plasma in head and neck cancer patients
- Abstract n. 58 : T. Meijer (NL) – Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas according to GLUT1 and MCT4 expression
- Abstract n. 46: P. Borghetti (I) - Has the

- Abstract n. 93: H. Kunogi (JP) – Prediction of radiosensitivity using phosphorylation of histone H2AX
- Abstract n. 74: M. Kriegs (D) - Inhibition of epidermal growth factor receptor enhances radiation-induced permanent G1 arrest solely in tumor cells with intact p53/p21 cell cycle regulation
- Abstract n. 121: G. Niedermann (D) - Delayed Cell Death Associated With Mitotic Catastrophe in Gamma-Irradiated Stem-like Glioma Cells
- Abstract n. 77: N. Cordes (D) – Glioma cell migration in 3D is not impaired by ionizing radiation
- Abstract n. 63: C. Toulas (F) - In vivo radiosensitizer effect of the HDAC inhibitor S78454 on orthotopic human glioblastoma.
- Abstract n. 311: U. Raju (USA) - Tumor microenvironment and integrins as effective therapeutic targets to improve radiotherapy outcome
- Abstract n. 105 : D. Viertl (CH) - A TAT-RasGAP derived peptide efficiently sensitizes cancer cells to radiotherapy, an in vitro and in vivo study
- Abstract n. 378 : T. Rieckmann (D) (CH) - HNSCC cell lines positive for HPV and p16 possess an exceptionally high radiosensitivity

	quality of vessels a value in the treatment of Glioblastoma Multiforme? A study on the role of GLUT1 in neoangiogenesis. • Abstract n. 109: L. Koi (D) - Tumour microenvironment and intratumoural distribution of therapeutic antibodies • Abstract n. 152: N. Cordes (D) – Cetuximab is an efficient carrier of radionuclides to target EGFR-expressing tumor cells • Abstract n. 100: W. Kam (AUS) – The response of messenger RNA to ionizing radiation – mitochondrial genes are more susceptible • Abstract n. 28: F. Meyer (CAN) – Genetic sequence variants in relation to acute and late toxicities in patients with head and neck cancer treated with radiation therapy	
Lunch		
Plenary: G. Adams Lecture **Translating chemical concepts into clinical treatments: Not a quick fix.** **I. Stratford, UK**		
Targeting signaling pathways ***Chair: D. Zips (D), E. Deutsch (F)***	**Biological and physical optimization of treatment plans** ***Chair: S.M. Bentzen (USA), T. Collen (CH)***	**Normal tissues** ***Chair: J. Overgaard (DK), H-P. Rodemann (D)***
• Modulation of Chk1 signalling during radiation therapy. K. Harrington, UK • Epigenetic regulation by HRR by microvascular dysfunction determines tumor cure by SDRT. Z. Fuks, USA	• A systems biology approach to radiation therapy optimization. A. Brahme, SW ***(tbc)*** • Automation in beam modeling and quality control. D.A. Jaffray, CAN • Better IMRT: First clinical experience with	• Cardiovascular mediated damage after irradiation. F.A. Stewart, NL • Latest progresses on modulation of heart radiation side effects. M.C. Vozenin, F • Lung toxicity: where to go from here?

• Mechanisms of EGFR inhibitors. Peter Rodemann, D • Regulation of paracrine signaling by microtubule stabilizing agents and ionizing radiation M. Pruschy, CH	multi-criteria optimization. T. Bortfeld, USA • Dose correction strategy for the optimization of volumetric modulated arc therapy. G. Mageras, USA	S.L. Tucker, USA • Scarce resources for nuclear detonation: project overview and challenges. C.N. Coleman, USA
Coffee		
Proffered papers: Physics (I) ***Chair: S. Bulling (CH)***	**Proffered papers: Biology (I)** ***Chair: J. Cox (USA)***	**Proffered papers: Clinics (I)** ***Chair: J. Bernier (CH)***
• Abstract n. 103: F. Fiedler (D) - Techniques for image based in-vivo dosimetry: from particle therapy PET to in-beam prompt gamma imaging • Abstract n. 19: S. Devic (CAN) - FDG-based Uptake Volume Histograms: Avenue towards Biological Target Volumes • Abstract n. 240: E. Rusten (NO) - Spatial correlations between images derived from dynamic FDG-PET • Abstract n. 22: C. Halle (NO) - Visualizing an aggressive hypoxia phenotype of cervical cancer using DCE-MR imaging • Abstract n. 55: T. Roland (USA) - Real time Image Guided Radiotherapy for Pancreatic Tumors - The Concept of Dual Modality Monitoring Using kV-CBCT and Robot Assisted Ultrasound Imaging • Abstract n. 65: J. Wong (USA) – Integrated on-board X-Ray and bioluminescence tomography to guide focal irradiation of soft tissue targets in small animals • Abstract n. 119: S. Broggi (I) – Quantitative parameters of parotid deformation during IMRT for …	• Abstract n. 316: K. Mizuno (JAP) - SRXRF analysis on the accumulation of DACHPt-loaded polymeric micelles in tumor before and after irradiation • Abstract n. 184: M. Lando (NO) - Loss of chromosome 3P leads to downregulation of RYBP, TMF1, and PSMD6 and poor outcome after chemoradiotherapy of cervical cancer 16:20 Abstract n. 80: T.E. Schmid (D) - Serum Hsp70 - a soluble, tumor-specific marker in xenograft tumor mouse models • Abstract n. 7: A. Sharma (USA) - Chemotherapeutic activity of s-nitrosoglutathione alone and in combination with cisplatin and radiation in head and neck cancer cells and mouse xenograft model • Abstract n. 43: M. Toulany (D) - Y-box binding protein-1 phosphorylation induced by ionizing radiation depends on EGFR kinase activity and K-RAS status • Abstract n. 53: P. Pedicini (I) - Combination of radiation and monoclonal antibody EGFR inhibitors in the Head and Neck tumors • Abstract n. 61: H. Stegeman (NL) - Effects of EGFR-inhibition and radiotherapy on	• Abstract n. 186: V. Carillo (I) – Correlating surrogates for bladder dosimetry with the dose-volume histogram of bladder wall defined on T2W-MRI imaging • Abstract n. 264: M. Thor (DK) - M. Lando (NO) - Bladder dose accumulation in prostate IMRT based on a biomechanical deformable image registration algorithm • Abstract n. 242: A. Erlend (NO) - Imaging parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome • Abstract n. 280: Herrera F (CH) - Simultaneous Integrated Boost in Cervix Cancer: Too Much Uncertainty • Abstract n. 193: K. Snipstad (NO) – repression of membranous moesin leads to evasion of the immune response and chemoradioresistance in cervical cancer • Abstract n. 266: R. Madan (IND) – Comparison of conventional point A based treatment planning with 3D CT based treatment planning in carcinoma of the cervix • Abstract n. 267: T. Vuong (CAN) - Impact of timing of chemotherapy in the treatment of

- Abstract n. 110: F. Lakosi (B) - Comparison of respiration-related surgical clip and chest wall movement between prone and supine position in the adjuvant radiotherapy of breast cancer
- Abstract n. 15 A. Vakili (IRAN) - Evaluation of radiolabeling monoclonal anti-EGFR antibody (Cetuximab) with Samarium-153, Yttrium-90 and cupper-64 for radioimmunotherapy
- Abstract n. 33: N. Tomic (CAN) - Linearization of the radiochromic film dosimetry system dose response

hypoxia, proliferation and tumor growth delay in human tumor xenografts

- Abstract n. 287: E. Sulman (USA) - Combining Molecular and Clinical Factors to Predict Survival of Patients with Glioblastoma and Validation using RTOG 0525
- Abstract n. 99: T. Dasgupta (USA) - BRAF V600E inhibitor PLX4720 enhances the effect of RT in vivo and in vitro in Pediatric High Grade Gliomas Expressing the BRAFV600E mutation
- Abstract n. 125: J. Doyen (FR) - Prognostic value of chromosomal imbalancies and the colon gene expression signatures in rectal cancer

patients with operable rectal cancer: Preliminary results from a randomized phase II study

- Abstract n. 178: P. Martinive (B) - Tailoring the timing of surgery based on the neoadjuvant radiotherapy schedule for decreasing tumor dissemination at the time of surgical procedure.
- Abstract n. 145: T. Rancati (I) - Rectal toxicity 6 years after high-dose radiation for prostate cancer: clinical and dosimetric predictors
- Abstract n. 35: M. Nagarajan (IND) - Resource Sparing Short Course Radiation Vs Long Course Radiation to Palliate Esophageal Cancer after Brachytherapy: A Report of Randomized Trial IAEA E33027

Friday

Session 1	Session 2	Session 3
Proffered papers (winning posters)	**Proffered papers**	**Proffered papers**

• Winning poster from
  ○ Radiobiology in Therapy and Space Science
  ○ Radioisotopes in Diagnostics and Therapy
  ○ Prospects in Detectors and Medical Imaging
  ○ Novel Technologies in Radiation Therapy
  ○ ICTR
	TBA	TBA

Towards customized treatments: the head-and-neck cancer example ***Chair: M. Baumann (D), J.C. Horiot (CH)***	**Molecular biology and predictive markers** ***Chair: K. Haustermans (B), D. Aebersold (CH)***	**Hadrontherapy** ***Chair: D.R. Olsen (NOR), D. Weber (CH)***
• New insights in DNA repair targeting and radiotherapy in head and neck cancer. D. Raben • Diffusion-weighted MRI for early tumour response assessment during treatment. V. Vandecaveye, B • Hypoxic modification of radiotherapy: old challenges, new solutions? J. Overgaard, DK • Chemoradiation versus induction chemotherapy in locally advanced head-and-neck carcinomas. J. Bourhis, F	• Candidate SNP vs genome-wide association scan of late radiotherapy toxicity: the RAPPER study. G. Barnett, UK • Molecular biology of radiation effects in normal tissues. W. Dörr, D • Molecular imaging as a biomarker. R. Jeraj, USA • Tumor hypoxia assays – ready for clinical use? M. Nordsmark, DK	• The imperative to transition from passively scattered to scanned proton beam delivery. T.F. Delaney, USA • Dose falloff in proton craniospinal irradiation: where and why? P.A.S. Johnstone, USA • Innovative and efficient dose calculation strategies for intensity modulated and passively scattered proton therapy. R. Mohan, USA • Toxicity and Patterns of Failure of Adaptive Proton Therapy. J.D. Cox, USA

Coffee		
Repair mechanisms ***Chair: M. Hauer-Jensen (USA), A. Allal (CH)***	**Functional imaging**	**Radiosensitivity modulation** ***Chair: M. Verheij (NL), M. Pruschy (CH)***
• DNA repair targeting and radiotherapy. A focus on the therapeutic ratio. R.G. Bristow, USA • Enhancing radiotherapy through a greater understanding of homologous recombination. S.N. Powell, USA • Effect of epidermal growth factor receptor on double-strand break repair. E. Dikomey, D • Targeting hypoxic cells through the DNA damage response. E. Hammond, UK	• Molecular imaging in planning head-and-neck cancer treatments. V. Grégoire, B • The role of adaptive and functional imaging modalities. D. Brizel, USA	• Influence of circulating normal cells on tumor radiosensitivity. J.M. Brown, USA • Targeting DNA repair as a sensitization strategy in radiotherapy. C. Vens, NL ***(tbc)*** • Impact of epithelial-to-mesenchymal transition on tumor response to radiation and targeted agents. R. Meyn, USA • Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors. A.J. Chalmers, UK
Lunch		
Tumor hypoxia and tumor metabolism ***Chair: C. Vrieling (CH)***	**Finding the target, restoring the vision.** ***Chair: J.M. Brown (USA), A. Chalmers (UK)***	**Improving precision in treatment planning and delivery** ***Chair: M. van Herk (NL)***
• Novel mechanisms of gene regulation by hypoxia. B. Wouters, CAN • Hypoxia in lung cancer models: implications for targeted therapeutics. A.J. Giaccia, USA ***(tbc)*** • Novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. T. Robson, IRL	• Angiogenic inhibitors and radiotherapy. E. Cohen-Jonathan Moyal, F • Apoptosis-modulating strategies to enhance radiation efficacy. M. Verheij, NL • Hypoxia inhibits disulfide bond formation and protein folding in the endoplasmic reticulum. M. Koritzinsky, CAN	• Improving the precision of dose delivery in the clinic. J.J.Sonke, NL • Biology-guided adaptive radiation therapy: present and future. C. Grau, DK • Stereotactic Radiation Therapy for Hepatocellular Carcinoma. L. Dawson, CA • Dose painting using volumetric modulated

		arc optimization and delivery. S. Korreman
Proffered papers: Physics (II) ***Chair: S.M. Bentzen (USA)***	**Proffered papers: Biology (II)** ***Chair: M. Nordsmark (DK)***	**Proffered papers: Clinics (II)** ***Chair: J.C. Horiot (CH)***
• Abstract n. 314: Brock K. (USA) - Generation of a Multi-Modality Anatomical Atlas of Preclinical Animal Models • Abstract n. 126: B. Reniers (NL) - In-vivo dosimetry for gynaecological brachytherapy using a novel detector system • Abstract n. 225: M. Casiraghi (CH) - A simulation and experimental based comparison of plan robustness for VMAT and IMPT treatments. • Abstract n. 333: I. Madani (B) – Volume changes by exploiting continuous adaptive radiotherapy for head and neck cancer • Abstract n. 36: M. Fix (CH) – Towards proton treatment planning using macro Monte Carlo • Abstract n. 322: T. Lomax (CH) - Intensity Modulated 'Grid' Proton Therapy. Trying to exploit 'spatial fractionation' with protons. • Abstract n. 41: D. Nichiporov (USA) – Potential applications of a gas electron multiplier-based detector to small field dosimetry and imaging in proton therapy • Abstract n. 25: B. Jones (UK) - Physical Dose Distribution and Relative Biological Effect (RBE) Issues in Proton Beam Therapy of Medulloblastoma • Abstract n. 173: A. Rucinski (D) - Target Volume Optimization for Prostate Cancer Treatment in Carbon Ion Radiation Therapy	• Abstract n. 70: M. Horsman (DK) – Constitutive and induced hypoxia in tumours and their role in the interaction between vascular disrupting agents and radiation • Abstract n. 76: A. Broggini-Tenzer (CH) - Dynamic Changes of the Tumor Micromilieu under Treatment • Abstract n. 198: A. Deviers (F) – Lactate detection with magnetic resonance spectroscopic imaging (MRSI) in glioblastoma multiforme before radiotherapy (RT): Characterization of hypoxia distribution and its impact on tumor response to • Abstract n. 233: C. Bayer (D) - The influence of the heat shock protein 90 (Hsp90) inhibitor, NVP-AUY922, and hypoxia on the expression of and HIF-1? and HIF-2? in two head and neck cancer cell lines • Abstract n. 128: K. Toustrup (DK) – Hypoxic modification of radiotherapy with nimorazole in Head and neck squamous cell carcinomas: importance of combined hypoxia and HPV classification when distinguishing responders from non-responders • Abstract n. 44: M. Nijkamp (NL) – Involvement of the epidermal growth factor receptor in laryngeal cancer patients treated with hypoxia modification as an additive to accelerated radiotherapy	• Abstract n. 140: A. Fairchild (B) - Does Quality of Radiotherapy Predict Outcomes of Multicentre Cooperative Group Trials? A Literature Review • Abstract n. 49: R. Komaki (USA) - Phase II study erlotinib/RT and CHT/RT followed by consolidation of CHT for patients with stage III Non-small cell lung cancer (NSCLC): analysis of patients specimens for biomarkers • Abstract n. 81: D. Guest (UK) - Mathematical Modelling of a Radiobiologically Optimised Fractionation Schedule for a Heterogeneously Differentiated Cell Model of Glioblastoma • Abstract n. 209: A. Laprie (F) - MR Spectroscopy imaging (MRSI) for glioblastoma dose painting with intensity modulated radiation therapy comprising simultaneous integrated boost on specific targets • Abstract n. 90: J. Zeng (USA) – Combining anti-PD-1 immunotherapy with stereotactic radiosurgery in a mouse orthotopic glioblastoma model • Abstract n. 263: U.V. Elstrom (DK) - A direct comparison of cone-beam CT versus CT based radiotherapy planning in head and neck cancer • Abstract n. 147: K. Roe (NO) - DCEMRI in assessment of tumor neovascularization after androgen-deprivation in experimental

in the Presence of Interfractional Motion	• Abstract n. 195: H.B. Ragnum (NO) - Androgen deprivation therapy prior to irradiation of prostate cancer: Expression of hypoxia-induced proteins and changes in diffusion weighted MRI parameters • Abstract n. 14: S. Rademakers (NL) – Predictive value of CAIX expression and staining pattern in patients with laryngeal cancer treated in the phase III randomized ARCON trial • Abstract n. 18: S. Masunaga (JP) – Impact of employing 10B- carriers and manipulating intratumor hypoxia on local tumor response and lung metastatic potential in boron neutron capture therapy • Abstract n. 326: F. Paris (F) – Specific protection of gastro-intestinal side effect, but not aggressive tumors by injection of exogenous sphingosine 1 phosphate	prostate cancer: correlation to quantitative immunohistochemistry • Abstract n. 291: J. Hammer (A) - Breast Cancer: Persisting risks in pre-menopausal women after breast conserving surgery, radiotherapy, +/- systemic therapies • Abstract n. 290: M. Carrara (I) - Predicting late faecal incontinence after high-dose radiotherapy for prostate cancer: application of artificial neural network classification on a longitudinal definition

European School of Oncology
Plenary Session
Chair: A. Costa (I)

- Hypofractionation in breast cancer irradiation.
  S.M. Bentzen, USA
- Intra-operative radiotherapy of early breast cancer.
  R. Orecchia, I

E. van der Schueren Award (MD Anderson Cancer Center, Houston)
Chair: A. Costa (I)

- Biomarkers in Head and Neck Carcinoma.
  K.K. Ang, USA

Closing session (M. Dosanjh and J. Bernier)